Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy

Dyne Therapeutics, Inc. announced that the FDA has granted Fast Track designation for DYNE-251 for the treatment of Duchenne muscular dystrophy mutations amenable to exon 51 skipping.